Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Spike protein that mediates coronavirus entry into host cells is a major target for COVID-19 vaccines and antibody therapeutics. However, multiple variants of SARS-CoV-2 have emerged, which may potentially compromise vaccine effectiveness. Using a pseudovirus-based assay, we evaluated SARS-CoV-2 cell entry mediated by the viral Spike B.1.617 and B.1.1.7 variants. We also compared the neutralization ability of monoclonal antibodies from convalescent sera and neutralizing antibodies (NAbs) elicited by CoronaVac (inactivated vaccine) and ZF2001 (RBD-subunit vaccine) against B.1.617 and B.1.1.7 variants. Our results showed that, compared to D614G and B.1.1.7 variants, B.1.617 shows enhanced viral entry and membrane fusion, as well as more resistant to antibody neutralization. These findings have important implications for understanding viral infectivity and for immunization policy against SARS-CoV-2 variants.

Related collections

Author and article information

Journal

Journal ID (nlm-ta): Genes Dis

Journal ID (iso-abbrev): Genes Dis

Title: Genes & Diseases

Publisher: Chongqing Medical University. Production and hosting by Elsevier B.V.

ISSN (Print): 2352-4820

ISSN (Electronic): 2352-3042

Publication date PMC-release: 3 December 2021

Publication date (Electronic): 3 December 2021

Affiliations

[a ]Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, PR China

[b ]Yong-Chuan Hospital, Chongqing Medical University, Chongqing 402177, PR China

[c ]Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing 400016, PR China

Author notes

[∗ ]Corresponding author. Tel.: +86 23-68486780; fax: +86 23-68486780; .

[∗∗ ]Corresponding author. Tel.: +86 23-68486780; fax: +86 23-68486780; .

[∗∗∗ ]Corresponding authors. Tel.: +86 23-68486780; fax: +86 23-68486780; .

[∗∗∗∗ ]Corresponding author. Tel.: +86 23-68486780; fax: +86 23-68486780;

[1]

These authors contributed equally to this work.

Article

Publisher Item ID: S2352-3042(21)00155-0

DOI: 10.1016/j.gendis.2021.11.007

PMC ID: 8639289

PubMed ID: 34877393

SO-VID: 4f2a7852-9738-4e69-a7c5-3dacde78922e

License:

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

History

Date received : 11 July 2021

Date revision received : 26 September 2021

Date accepted : 5 November 2021

Comments

Comment on this article

scite_

Cited by 6

See all cited by